Nanjing Leads Biolabs Co., Ltd. (Stock Code: 9887) announced that on November 25, 2025, its board of directors approved the proposed adoption of an H Share Award Scheme, alongside the proposed cancellation of its Supervisory Committee and corresponding amendments to the Articles of Association. The scheme is intended to promote long-term sustainable development, align the interests of eligible participants with those of shareholders, and enhance the company's incentive mechanism.
Key terms of the H Share Award Scheme include a seven-year duration from the date of adoption, with a maximum of 10% of the total issued shares (excluding treasury shares)—equating to 19,889,180 H Shares—available as Target Shares, half of which will be acquired from the market and half through new issuance. Within this total, newly issued shares under the scheme may not exceed 5% of the total shares in issue, amounting to a Scheme Mandate Limit of 9,944,590 shares, while a separate 1% Service Provider Sublimit is also recognized. The scheme outlines performance targets, a minimum vesting period of 12 months, and a requirement that vesting criteria be satisfied for any awarded shares to vest.
In addition, the board resolved to cancel the Supervisory Committee to further enhance corporate governance, transferring its functions to the Audit Committee. Corresponding amendments to the Articles of Association and the adoption of the H Share Award Scheme are subject to approval by special resolutions at an upcoming extraordinary general meeting.
Comments